

**YOUR INVITATION TO
A LIVE WEBCAST**

*Early Introduction of Anti-TNF Therapy
for Ulcerative Colitis and Crohn's
Disease Management*

Speakers



Edouard Louis, MD, PhD
Head of the Department of Gastroenterology
Liège University Hospital
Liège, Belgium



Alessandro Armuzzi, MD, PhD
Consultant in Internal Medicine and Gastroenterology
Internal Medicine and Gastroenterology Unit
Complesso Integrato Columbus
Catholic University of the Sacred Heart
Rome, Italy





Afternoon

Why attend?

This 1-hour webcast will focus on the importance of early anti-tumor necrosis factor (TNF) therapy in altering the course of disease in both Crohn's disease (CD) and ulcerative colitis (UC) patients, review the efficacy of this class of biologics in early disease, and highlight the importance of maintaining and optimizing

anti-TNF therapy to improve patient outcomes.

In the session titled "Should We Be Introducing Anti-TNF Therapy Earlier?" Alessandro Armuzzi, MD, PhD, will discuss the definitions of early disease and emerging clinical assessments in CD and UC and describe the best treatment approaches in both indications. Edouard Louis, MD, PhD, will present the session titled "Maintenance Therapy and Optimization of Anti-TNF Therapy," which will focus on the benefits of maintenance and optimization of anti-TNF therapy and address the question of when it is appropriate to switch or discontinue therapy.

Register at <http://gastro-2013-webcast-optimize-anti-tnf-therapy-afternoon.msd.com>

To register for the free live webcast, please go to <http://gastro-2013-webcast-optimize-anti-tnf-therapy-afternoon.msd.com>.

You will then receive a confirmation-of-registration e-mail with further details.

How it works

View from your office or home.

In your confirmation e-mail, you will receive a Web site link to the webcast and log-in details that will give you free access to view the webcast online. The registration e-mail will also contain details on testing your computer beforehand to make sure that it is compatible.

MONDAY, 27 MAY 2013: 16:00h (Central European SUMMER Time)

Agenda

16:00	Welcome and Introduction	Edouard Louis, MD, PhD (Liège, Belgium)
16:05	Should We Be Introducing Anti-TNF Therapy Earlier?	Alessandro Armuzzi, MD, PhD (Rome, Italy)
16:25	Maintenance Therapy and Optimization of Anti-TNF Therapy	Edouard Louis, MD, PhD
16:45	Questions and Answers	Edouard Louis, MD, PhD, and Alessandro Armuzzi, MD, PhD
16:55	Closing Remarks	Edouard Louis, MD, PhD



Evening

Why attend?

This 1-hour webcast will focus on the importance of early anti-tumor necrosis factor (TNF) therapy in altering the course of disease in both Crohn's disease (CD) and ulcerative colitis (UC) patients, review the efficacy of this class of biologics in early disease, and highlight the importance of maintaining and optimizing anti-TNF therapy to improve patient outcomes.

In the session titled "Should We Be Introducing Anti-TNF Therapy Earlier?" Alessandro Armuzzi, MD, PhD, will discuss the definitions of early disease and emerging clinical assessments in CD and UC and describe the best treatment approaches in both indications. Edouard Louis, MD, PhD, will present the session titled "Maintenance Therapy and Optimization of Anti-TNF Therapy," which will focus on the benefits of maintenance and optimization of anti-TNF therapy and address the question of when it is appropriate to switch or discontinue therapy.

Register at <http://gastro-2013-webcast-optimize-anti-tnf-therapy-evening.msd.com>

To register for the free live webcast, please go to <http://gastro-2013-webcast-optimize-anti-tnf-therapy-evening.msd.com>.

You will then receive a confirmation-of-registration e-mail with further details.

How it works

View from your office or home.

In your confirmation e-mail, you will receive a Web site link to the webcast and log-in details that will give you free access to view the webcast online. The registration e-mail will also contain details on testing your computer beforehand to make sure that it is compatible.

MONDAY, 27 MAY 2013: 19:30h (Central European SUMMER Time)

Agenda

19:30	Welcome and Introduction	Edouard Louis, MD, PhD (Liège, Belgium)
19:35	Should We Be Introducing Anti-TNF Therapy Earlier?	Alessandro Armuzzi, MD, PhD (Rome, Italy)
19:55	Maintenance Therapy and Optimization of Anti-TNF Therapy	Edouard Louis, MD, PhD
20:15	Questions and Answers	Edouard Louis, MD, PhD, and Alessandro Armuzzi, MD, PhD
20:25	Closing Remarks	Edouard Louis, MD, PhD